Compass Therapeutics Announces Participation in March 2021 Investor Conferences

Rhea-AI Summary

Compass Therapeutics, Inc. (OTCQB: CMPX) announced the participation of CEO Thomas Schuetz in two virtual investor conferences: the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, and the 33rd Annual Roth Conference on March 15-17, 2021. The H.C. Wainwright presentation will be available on demand, while a live panel discussion on bispecific antibodies will occur on March 16, 2021. Compass Therapeutics is focused on developing proprietary antibody therapeutics targeting solid tumors and hematological malignancies, including its lead candidate, CTX-471, in a Phase 1b study.

Positive

• CEO Thomas Schuetz to present at two significant investor conferences, potentially increasing visibility.
• Continued development of lead product candidate CTX-471, which is currently in a Phase 1b study.

Negative

• None.

Compass Therapeutics, Inc. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Co-Founder and Chief Executive Officer of Compass Therapeutics, will participate in the following virtual investor conferences:

• H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021: Compass presentation will be broadcasted at 7:00 a.m. EST on March 9, 2021 and available on demand during the conference.

• 33rd Annual Roth Conference, March 15-17, 2021: as part of a live panel on bispecific antibodies that will take place at 3:00 p.m. EDT on Tuesday, March 16, 2021.

A replay of Compass presentation will be available after the completion of the H.C. Wainwright Global Life Sciences Conference in the “Investors – Events and Presentations” tab on the Compass website www.compasstherapeutics.com.

About Compass Therapeutics

Compass Therapeutics, Inc. (OTCQB: CMPX), is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematologic malignancies. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system. The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, and is currently being evaluated in a Phase 1b study. The Company’s offices and labs are located in Boston, MA. Its website is at www.compasstherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to our product candidates and the development and therapeutic potential thereof, our technologies for identifying additional product candidates, and our business and development plans. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, our ability to identify additional product candidates for development, our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, and competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and Compass assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation our Form 10-Q for the quarter ended September 30, 2020, and our subsequent filings with the SEC.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210304006143/en/

FAQ

What investor conferences will CMPX's CEO be attending in March 2021?

CMPX's CEO will be attending the H.C. Wainwright Global Life Sciences Conference from March 9-10 and the 33rd Annual Roth Conference from March 15-17, 2021.

What is the focus of Compass Therapeutics, Inc.?

Compass Therapeutics focuses on developing proprietary antibody therapeutics to engage the immune system in treating solid tumors and hematological malignancies.

What is the lead product candidate for CMPX?

The lead product candidate for CMPX is CTX-471, a fully human agonistic antibody of CD137, currently in a Phase 1b study.

Where can I find the replay of CMPX's presentation from the H.C. Wainwright conference?

The replay of CMPX's presentation will be available in the 'Investors – Events and Presentations' tab on their website after the conference.

What are the potential risks mentioned in CMPX's press release?

The press release outlines risks such as the ability to raise additional funding and uncertainties related to product development and clinical trials.